Seattle, WA -- (SBWIRE) -- 10/02/2019 -- Human growth hormone is a peptide hormone that is naturally produced in the pituitary glands. It stimulates growth, cell reproduction, and cell regeneration. The somatotropic cells within the lateral wings of anterior pituitary gland store and secrete growth hormone. These hormones are responsible for general growth of the body and mineralization of the bones. Growth hormones also help to retain calcium in the body and increases muscle mass through sarcomere hypertrophy. The hormones promote lipolysis, increase protein synthesis, and stimulate growth of all internal organs excluding the brain. Growth hormones are responsible for homeostasis, decrease in uptake of glucose by liver, stimulation in the immune system, and increase of DE iodination of T4 to T3.
However, uncontrolled or excess secretion of growth hormones can lead to pituitary tumor, which consists of somatotroph cells of the anterior pituitary. These somatotroph cells are benign in nature and gradually grow and produce excess of growth hormones. This may often lead to headaches, pressure on optic nerves causing impaired vision, deficiency of other hormones secreted by pituitary gland, and thickening of the bones of jaw, toes, and fingers, which eventually results in heaviness of jaws and increase in size of digits called as acromegaly. Acromegaly can further lead to pressure on nerves, muscle weakness, and reduced sexual function. Growth hormone deficiency is associated with failure in growth, increase in osteoclast activities, weakening of bones, trauma, increase in fat mass, and decrease in muscle mass.
Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1859
Key players in the market are focused on adopting merger and acquisition strategies, which is expected to boost growth of the market. For instance, in 2014, Pfizer Inc., a U.S.-based pharmaceutical company, merged with OPKO Health Inc., a U.S.-based company, to develop a long acting growth hormone (hGH-CTP) and to bring innovative treatments for growth hormone deficient patients. hGH-CTP is more convenient, as the patients need to take just one injection in a week rather than daily doses. hGH-CTP has an orphan drug designation in the U.S. and Europe for adults and children with growth hormone deficiency.
Robust pipeline of advanced products for the treatment of growth hormone deficiency is also expected to propel growth of the market. For instance, Somapacitan sponsored by Novo Nordisk A/S, a Denmark-based company, completed phase 3 clinical trials in 2017. This drug is used for the treatment of growth hormone deficiency in adults. MOD-4023 sponsored by Opko Biologics, an Israel-based company, completed phase 2 clinical trials in 2015. High prevalence of growth hormone deficiency is another factor boosting growth of human growth hormone market. According to a survey conducted by the National Organization for Rare Diseases (NORA) in 2015, over 10,000 children and 50,000 adults have growth hormone deficiency in the U.S.
Key players in the Europe market are focused on adopting merger and acquisition strategies, which is expected to contribute to growth of the market. For instance, in 2017, Ferring Pharmaceuticals S.A., a pharmaceutical company, acquired a product i.e. Zoma Jet of Antares Pharma Inc, a pharmaceutical company. Zoma Jet is a needle free auto injectable device. Ferring Pharmaceuticals S.A acquired Zoma Jet in order to increase use of Zomacton (Injectable somatropin hGH). Zoma Jet is used to deliver Zomacton for the treatment of growth hormone deficiency in children and Turner's syndrome in girls. By acquiring the injectable device Zoma Jet, would eventually lead to increase in use of the drug, Zomacton, which will further encourage Ferring Pharmaceuticals to develop better treatment options for growth hormone deficiency, thereby resulting in growth of the human growth hormone market. Asia Pacific is expected to grow over the forecast period due to robust pipeline. For instance, Cinna Tropin sponsored by Cinnagen, an Iran-based company, completed phase 3 clinical trials in 2017. This drug is used to treat idiopathic short stature in children and adults.
Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1859
Human Growth Hormone Market Taxonomy:-
By Application
Growth Hormone Deficiency
Idiopathic short stature
Prader-Willi Syndrome
Turner Syndrome
Others
By Route of Administration
Oral
Intravenous
Subcutaneous
Intramuscular
By Distribution Channel
Hospitals
Retail Pharmacies
Online Pharmacies
By Region
North America
Europe
Latin America
Asia Pacific
Middle East
Africa
Human Growth Hormone Market Key Players:-
Key players operating in the global human growth hormone market include, Pfizer Inc., Genetech Inc., Merck & Co., Eli Lilly And Company, Novo Nordisk, Sandoz International GmbH, Ferring Holding SA, and Ipsen.
To view the original version on The Express Wire visit https://www.coherentmarketinsights.com/ongoing-insight/human-growth-hormone-market-1859
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.